These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 23918291)

  • 1. Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.
    Malenfant SJ; Eckmann KR; Barnett CM
    Pharmacotherapy; 2014 Jan; 34(1):60-71. PubMed ID: 23918291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
    Chung C; Lam MS
    Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
    Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
    De Mattos-Arruda L; Cortes J
    Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.
    O'Sullivan CC; Swain SM
    Expert Opin Biol Ther; 2013 May; 13(5):779-90. PubMed ID: 23530718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
    Baselga J; Swain SM
    Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pertuzumab in HER2-positive breast cancer.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
    Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
    Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.
    Rocca A; Andreis D; Fedeli A; Maltoni R; Sarti S; Cecconetto L; Pietri E; Schirone A; Bravaccini S; Serra P; Farolfi A; Amadori D
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1647-63. PubMed ID: 26307328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.
    Smith MB; Reardon J; Olson EM
    Drugs Today (Barc); 2012 Nov; 48(11):713-22. PubMed ID: 23170307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.
    Tian T; Ye J; Zhou S
    Int J Clin Pharmacol Ther; 2017 Sep; 55(9):720-727. PubMed ID: 28737130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
    Sabatier R; Gonçalves A
    Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.
    Amiri-Kordestani L; Wedam S; Zhang L; Tang S; Tilley A; Ibrahim A; Justice R; Pazdur R; Cortazar P
    Clin Cancer Res; 2014 Nov; 20(21):5359-64. PubMed ID: 25204553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.
    Cortés J; Fumoleau P; Bianchi GV; Petrella TM; Gelmon K; Pivot X; Verma S; Albanell J; Conte P; Lluch A; Salvagni S; Servent V; Gianni L; Scaltriti M; Ross GA; Dixon J; Szado T; Baselga J
    J Clin Oncol; 2012 May; 30(14):1594-600. PubMed ID: 22393084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertuzumab: development beyond breast cancer.
    Barthélémy P; Leblanc J; Goldbarg V; Wendling F; Kurtz JE
    Anticancer Res; 2014 Apr; 34(4):1483-91. PubMed ID: 24692675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.
    Dawood S; Sirohi B
    Future Oncol; 2015; 11(6):923-31. PubMed ID: 25760974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
    Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
    O'Sullivan CC; Connolly RM
    Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.
    Ajgal Z; de Percin S; Diéras V; Pierga JY; Campana F; Fourquet A; Kirova YM
    Cancer Radiother; 2017 Apr; 21(2):114-118. PubMed ID: 28347625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.